Clinical Impact of Radiotherapy to the Prostate in Patients with Low Burden of Metastatic Disease

Purpose: The STAMPEDE trial has recently shown a benefit in overall survival by irradiating the prostate of patients with newly diagnosed metastatic prostate cancer [1]. This benefit was only shown in patients with low burden of metastatic disease, as per the CHAARTED criteria [2]. The current standard of care for these patients is androgen deprivation therapy ± docetaxel chemotherapy and radiotherapy to symptomatic areas of disease if required. The aim of this audit is to determine the potential number of men with low burden of metastatic disease who may require additional radiotherapy.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research